Clinical Trials Logo

Citation(s)

  •   Kario K, Tamaki Y, Okino N, Gotou H, Zhu M, Zhang J
    LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension. J Clin Hypertens (Greenwich). 2015 Sep 24. doi: 10.1111/jch.12667.

A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension

Details for clinical trial NCT01646671